X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs PLETHICO PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD PLETHICO PHARMA BIOCON LTD/
PLETHICO PHARMA
 
P/E (TTM) x 82.9 -1.1 - View Chart
P/BV x 7.8 0.0 46,537.4% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 BIOCON LTD   PLETHICO PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
PLETHICO PHARMA
Mar-14
BIOCON LTD/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,162395 294.2%   
Low Rs48331 1,541.5%   
Sales per share (Unadj.) Rs194.6604.4 32.2%  
Earnings per share (Unadj.) Rs34.432.5 105.9%  
Cash flow per share (Unadj.) Rs48.351.3 94.0%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs241.9473.6 51.1%  
Shares outstanding (eoy) m200.0034.08 586.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.20.4 1,198.6%   
Avg P/E ratio x23.96.6 364.2%  
P/CF ratio (eoy) x17.04.2 410.3%  
Price / Book Value ratio x3.40.5 755.4%  
Dividend payout %2.90-   
Avg Mkt Cap Rs m164,4407,262 2,264.3%   
No. of employees `0009.2NA-   
Total wages/salary Rs m7,4701,596 468.0%   
Avg. sales/employee Rs Th4,213.9NM-  
Avg. wages/employee Rs Th809.0NM-  
Avg. net profit/employee Rs Th745.2NM-  
INCOME DATA
Net Sales Rs m38,91120,598 188.9%  
Other income Rs m1,571386 406.6%   
Total revenues Rs m40,48220,984 192.9%   
Gross profit Rs m9,7952,818 347.6%  
Depreciation Rs m2,772642 431.6%   
Interest Rs m2601,593 16.3%   
Profit before tax Rs m8,334969 860.5%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,616-138 -1,167.8%   
Profit after tax Rs m6,8811,107 621.7%  
Gross profit margin %25.213.7 184.0%  
Effective tax rate %19.4-14.3 -135.7%   
Net profit margin %17.75.4 329.1%  
BALANCE SHEET DATA
Current assets Rs m40,47718,877 214.4%   
Current liabilities Rs m16,78311,896 141.1%   
Net working cap to sales %60.933.9 179.7%  
Current ratio x2.41.6 152.0%  
Inventory Days Days6036 165.8%  
Debtors Days Days83198 41.9%  
Net fixed assets Rs m45,0739,861 457.1%   
Share capital Rs m1,000341 293.5%   
"Free" reserves Rs m47,37712,331 384.2%   
Net worth Rs m48,37716,139 299.8%   
Long term debt Rs m21,0824,706 448.0%   
Total assets Rs m93,94233,146 283.4%  
Interest coverage x33.11.6 2,055.7%   
Debt to equity ratio x0.40.3 149.5%  
Sales to assets ratio x0.40.6 66.7%   
Return on assets %7.68.1 93.3%  
Return on equity %14.26.9 207.4%  
Return on capital %12.612.3 102.6%  
Exports to sales %021.4 0.0%   
Imports to sales %015.2 0.0%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs mNA3,136 0.0%   
Fx inflow Rs m12,9884,402 295.0%   
Fx outflow Rs m7,8993,184 248.1%   
Net fx Rs m5,0891,219 417.6%   
CASH FLOW
From Operations Rs m6,4002,437 262.6%  
From Investments Rs m-4,985-6,265 79.6%  
From Financial Activity Rs m-1,7752,490 -71.3%  
Net Cashflow Rs m-473-1,337 35.4%  

Share Holding

Indian Promoters % 40.4 82.7 48.9%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 4.3 195.3%  
FIIs % 10.7 5.5 194.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 7.5 265.3%  
Shareholders   109,995 10,665 1,031.4%  
Pledged promoter(s) holding % 0.0 85.7 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   STRIDES SHASUN LTD  ELDER PHARMA  SUVEN LIFE  ALEMBIC PHARMA  WOCKHARDT LTD.  

Compare BIOCON LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS